Sign In
Buy AVXL
$2.65
-0.140 (-5.03%)
At Close: Jun 03, 2026
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
12:21pm, Thursday, 15'th May 2025
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to Euro
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
07:30am, Wednesday, 14'th May 2025
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
09:25am, Tuesday, 13'th May 2025
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Ex
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
07:30am, Tuesday, 13'th May 2025
Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
07:30am, Tuesday, 06'th May 2025
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
07:30am, Thursday, 01'st May 2025
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrol
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
07:30am, Wednesday, 30'th Apr 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
07:30am, Wednesday, 23'rd Apr 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and c
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
07:30am, Monday, 31'st Mar 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
07:30am, Monday, 24'th Feb 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
06:02pm, Friday, 14'th Feb 2025
Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine s
Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025
03:13pm, Wednesday, 12'th Feb 2025
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheim
Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript
09:59am, Wednesday, 12'th Feb 2025
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch
